Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study

Alissa Visram, Hsien Seow, Gregory Pond, Ana Gayowsky, Arleigh McCurdy, Christopher Cipkar, Hyra Sapru, C. Tom Kouroukis, Mohammed Aljama, Mohammad Ebraheem, Stephen Ronan Foley, Hira Mian

Blood (2023) 142 (Supplement 1): 3774.

https://doi.org/10.1182/blood-2023-190426

Published: 2023

Journal Articles

Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas

Amaris K. Balitsky, Gregory R Pond, Graeme Fraser, Tom Kouroukis, Stephen Ronan Foley

Blood (2022) 140 (Supplement 1): 8036–8037.

https://doi.org/10.1182/blood-2022-165674

Published: 2022

Journal Articles

Fitness Assessment of Elderly Patients with AML and Outcomes

Tony HT Chen, Joshua Xu, Hassan Zahreddine, Brian Leber, Irwin Walker, Tobias Berg, Kylie L. Lepic, Parveen Wasi, Tom Kouroukis, Christopher M. Hillis, Justin Y. Lee, Dina Khalaf

Blood (2021) 138 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2021-152612

Published: 2021

Journal Articles

Guiding the Standardization in Acute Leukemia Service Delivery through the Development of Organizational Requirements

Cassandra McKay, C. Tom Kouroukis, Sherrie Hertz, Rena J. Buckstein, Kardi Kennedy, Lia Kutzscher, Janet MacEachern, Mary Catherine McCann, Mitchell Sabloff, Karen Yee, Suzanna Apostolovski, Amanda Wong, Christopher Bredeson

Blood (2021) 138 (Supplement 1): 3013.

https://doi.org/10.1182/blood-2021-146171

Published: 2021

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD FRCPC, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Arleigh McCurdy, MD BSc, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Rami Kotb, MD, Darrell J White, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Anthony Reiman, MD, Fernando Camacho, PhD, Molei Fu, Engin Gul, BSc, Donna E. Reece, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-141087

Published: 2020

Journal Articles

Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort

Hira S Mian, MD, C. Tom Kouroukis, MDMSc,FRCPC, Gregory R Pond, PhD PStat, Hsien Seow, PhD, Jonathan Sussman, MD FRCPC, MSc

Blood (2019) 134 (Supplement_1): 268.

https://doi.org/10.1182/blood-2019-121672

Published: 2019

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD, Nizar Bahlis, MD, Christopher P. Venner, Arleigh McCurdy, MD, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Darrell J White, MD, Rami Kotb, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Tony Reiman, MD, Fernando Camacho, Julia Dobbin, Molei Fu, Engin Gul, BS, MBA, Donna E Reece, MD

Blood (2019) 134 (Supplement_1): 3121.

https://doi.org/10.1182/blood-2019-124457

Published: 2019

Journal Articles

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

James K R Stevenson, MD MSc, Lucy Qiao, MS, MPH, Kelvin Chan, MD PhD, Jaclyn Beca, MSc, Wanrundee Isaranuwatchai, PhD, Helen Guo, BS, Deborah Schwarz, PhD, Jessica Arias, BA, MACP, Scott Gavura, BSPharm, MBA, C. Tom Kouroukis, MDMSc,FRCPC, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 1557.

https://doi.org/10.1182/blood.V130.Suppl_1.1557.1557

Published: 2017

Journal Articles

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Zachary Liederman, MD, Neil Berinstein, MD, Michael Crump, MD, Jessica Hwang, MD MPH, Harry L.A. Janssen, PhD MD, C. Tom Kouroukis, MDMSc,FRCPC, Patricia Leung, Anna Lok, MD, Colina Yim, Andrew D. Zelenetz, MD PhD, Kelvin Chan, MD PhD, Jordan Feld, MD MPH, Lisa K. Hicks, MD MSc

Blood (2017) 130 (Supplement 1): 4697.

https://doi.org/10.1182/blood.V130.Suppl_1.4697.4697

Published: 2017

Journal Articles

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

Jonathan Wang, MASc, Andre C. Schuh, MD FRCPC, Deanna Wu, MBA, Christopher N. Bredeson, MD MSc, FRCPC, Jacinta Meharchand, MD FRCPC, Lisa Favell, MBA, Louis Fu, MISt, Kelly J. Woltman, MA, C. Tom Kouroukis, MDMSc,FRCPC

Blood (2017) 130 (Supplement 1): 3397.

https://doi.org/10.1182/blood.V130.Suppl_1.3397.3397

Published: 2017

Journal Articles

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Blood (2016) 128 (22): 3330.

https://doi.org/10.1182/blood.V128.22.3330.3330

Published: 2016

Journal Articles

Wait Times and Bed Capacity for Hematopoietic Cell Transplantation in Ontario: A System Dynamics Model

Jonathan Wang, MASc, Saba Vahid, PhD, Hertz Sherrie, BScPhm, C. Tom Kouroukis, MD MSc, FRCPC

Blood (2016) 128 (22): 2378.

https://doi.org/10.1182/blood.V128.22.2378.2378

Published: 2016

Journal Articles

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Tanya Skamene, MD, Wenyu Jiang, PhD, Ralph M. Meyer, MD, Michael Crump, MD, John Kuruvilla, MD, C. Tom Kouroukis, MD MSc, FRCPC, Stefano Luminari, Stephen Couban, MD, Matthew C. Cheung, MD SM, FRCPC, David A Rizzieri, MD, Peter G Bardy, MBBS, FRACP, FRCPA, Joseph Pater, MD MSc, Marina S. Djurfeldt, MSc, Lois E. Shepherd, MD, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 690.

https://doi.org/10.1182/blood.V128.22.690.690

Published: 2016

Journal Articles

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Blood (2016) 128 (22): 977.

https://doi.org/10.1182/blood.V128.22.977.977

Published: 2016

Journal Articles

Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone +/- Rituximab (CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)

Tom Kouroukis, MD, Winson Y. Cheung, Nizar Abdel-Samad, Sandeep Sehdev, Melanie Poulin-Costello, Brad Gillesby, Ewan J.D. Robson

Blood (2016) 128 (22): 3038.

https://doi.org/10.1182/blood.V128.22.3038.3038

Published: 2016

Journal Articles

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

John Kuruvilla, David A. MacDonald, C. Tom Kouroukis, Matthew Cheung, Harold J. Olney, A. Robert Turner, Peter Anglin, Matthew Seftel, Walid Sabry Ismail, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer, Annette E. Hay, Lois Shepherd, Marina S. Djurfeldt, Sameer Alamoudi, Bingshu E. Chen, Michael Crump

Blood (2015) 126 (6): 733–738.

https://doi.org/10.1182/blood-2015-01-622084

Published: 2015

Journal Articles

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

Annette E Hay, MB ChB, Alli Murugesan, PhD, Ashley M. DiPasquale, BSc, Tom Kouroukis, MD MSc, FRCPC, Irwindeep Sandhu, MD FRCPC, Vishal Kukreti, MD, Nizar J Bahlis, MD, Johan Lategan, MD, Donna E. Reece, MD, John F. Lyons, PhD, Joana Sederias, MSc, Jean Powers, MSc, Hao Xu, MSc, Lesley K. Seymour, MD PhD FRCP (C), Anthony Reiman, MD

Blood (2014) 124 (21): 5734.

https://doi.org/10.1182/blood.V124.21.5734.5734

Published: 2014

Journal Articles

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, MD, Bingshu E Chen, PhD, Stephen Couban, MD, C. Tom Kouroukis, MD MSc, FRCPC, Rena Buckstein, MD, John Kuruvilla, MD, Kang Howson-Jan, David Szwajcer, MD FRCPC, Massimo Federico, MD, Ralph M. Meyer, Robert Turner, MD, Marina S Djurfeldt, MSc, Annette E Hay, MB ChB, Lois Shepherd, MD, Michael Crump, MD

Blood (2014) 124 (21): 1712.

https://doi.org/10.1182/blood.V124.21.1712.1712

Published: 2014

Journal Articles

Cost-Utility Of Bortezomib In Induction Treatment Prior To Autologous Stem-Cell Transplantation (ASCT) In Previously Untreated Multiple Myeloma Patients In Canada

Tom Kouroukis, MD, MSc, FRCPC, Darrell White, MD, MSc, FRCPC, FACP, Morgan Kruse, BA, Donna Lawrence, MSc, Cristina Trambitas, BSc MBA, Matthew C. Cheung, MD, FRCPC

Blood (2013) 122 (21): 1735.

https://doi.org/10.1182/blood.V122.21.1735.1735

Published: 2013

Journal Articles

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Blood (2013) 122 (21): 155.

https://doi.org/10.1182/blood.V122.21.155.155

Published: 2013

NARROW

Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study

Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas

Fitness Assessment of Elderly Patients with AML and Outcomes

Guiding the Standardization in Acute Leukemia Service Delivery through the Development of Organizational Requirements

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Improved Survival in Overweight and Obese Patients with Non-Hodgkin's Lymphoma Treated with Rituximab Containing Chemotherapy for Curative Intent

HBV Care Map for Patients Receiving Anti-CD20 Therapy

Estimating the Need for Complex Malignant Hematologists in Ontario Using Monte Carlo Simulation

Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Wait Times and Bed Capacity for Hematopoietic Cell Transplantation in Ontario: A System Dynamics Model

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Granulocyte Colony-Stimulating Factor (GCSF) Use with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone +/- Rituximab (CHOP±R) Treatment for Aggressive Non-Hodgkin's Lymphoma (aNHL)

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Cost-Utility Of Bortezomib In Induction Treatment Prior To Autologous Stem-Cell Transplantation (ASCT) In Previously Untreated Multiple Myeloma Patients In Canada

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only